Stelara (ustekinumab) Letter of Medical Necessity
Stelara (ustekinumab) is frequently denied on first submission due to step therapy requirements that mandate failure of a TNF inhibitor. A well-constructed Letter of Medical Necessity citing prior failures, contraindications, or specific clinical features can overturn most denials.
FDA-Approved Indications
- ● plaque psoriasis
- ● psoriatic arthritis
- ● Crohn's disease
- ● ulcerative colitis
Why Stelara Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Step therapy: TNF inhibitor not tried first
- 2. Body Surface Area (BSA) or PASI score not documented
- 3. Biosimilar preferred (Wezlana, Selarsdi, etc.)
- 4. Induction vs maintenance dosing not specified
- 5. Concurrent immunosuppressant use not justified
What to Include in a Stelara Letter of Medical Necessity
Document the diagnosis with severity metrics (BSA, PASI, HBI, partial Mayo), prior therapy trials with dates and reasons for discontinuation, and the clinical rationale for IL-12/23 blockade — particularly relevant in patients with prior TNF failure, demyelinating disease history, or heart failure.
Key clinical evidence to cite:
- ✓ PHOENIX 1 & 2, PSUMMIT 1 & 2, UNITI-1, UNITI-2 trials
- ✓ Demonstrated superiority over placebo and non-inferiority to TNF inhibitors in select populations
- ✓ Long-term safety data showing favorable infection profile vs TNF class
Relevant guidelines:
- 📖 AAD-NPF 2019 Psoriasis Guidelines
- 📖 AGA 2020 Crohn's Guidelines
- 📖 GRAPPA 2021 PsA Recommendations
Stelara Prior Authorization Criteria
Standard criteria across major US payers for Stelara. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Step therapy: TNF inhibitor not tried first
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Stelara
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Stelara Prior Authorization FAQ
Why was my Stelara prior authorization denied?
The most common denial reasons for Stelara are: Step therapy: TNF inhibitor not tried first; Body Surface Area (BSA) or PASI score not documented; Biosimilar preferred (Wezlana, Selarsdi, etc.); Induction vs maintenance dosing not specified; Concurrent immunosuppressant use not justified.
What should a Stelara Letter of Medical Necessity include?
Document the diagnosis with severity metrics (BSA, PASI, HBI, partial Mayo), prior therapy trials with dates and reasons for discontinuation, and the clinical rationale for IL-12/23 blockade — particularly relevant in patients with prior TNF failure, demyelinating disease history, or heart failure.
Which payers cover Stelara?
Stelara is covered by major US payers including UnitedHealthcare, Aetna, Cigna, Blue Cross Blue Shield, Medicare Part D, though formulary tier and prior authorization criteria vary.